A Multicenter, Open Label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005% in Pediatric Subjects (Ages 2 to 11 Years) with Plaque Psoriasis

Main Article Content

Adelaide A Herbert
Debbie Glaab
Rhonda Schreiber

Keywords

Psoriasis, Calcipotriene, Corticosteroid, Halobetasol

Abstract

Abstract not available.

References

1. National Psoriasis Foundation 2019 July 31 About Psoriasis Retrieved from Psoriasis Org www psoriasis org/parents/about psoriasis

2. Silverberg, N B 2009 Pediatric Psoriasis An Update Therapeutics and Clinical Risk Management, 5 849-856

3. Kimball, A Gold, M Zib B Davis, M Clobetasol Propionate Emulsion Formulation Foam Ph 2008 Clobetasol propionate emulsion formulation foam 0 05 review of phase II open label and phase III randomized controlled trials in steroid responsive dermatoses in adults and adolescents JAAD, 59 3 448 454

4. Shah, K N 2013 Diagnosis and Treatment of Pediatric Psoriasis Current and Future American Journal of Clinical Dermatology, 14 195

5. Wolverton S E 2001 Comprehensive Dermatologic Drug Therapy XlX ed Philadelphia, PA Saunders

6 Feldman S R Mills, M Brundage, T Eastman, W J 2013 March) A multicenter, randomized, double blind study of the efficacy and safety of calcipotriene foam, 0 005 vs vehicle foam in the treatment of plaque type psoriasis of the scalp JDD, 12 3 300 306

7 Hebert, A Glaab, D Schrieber R 2019 A Phase 1 Open Label Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0 005 Applied Under Maximum Use Conditions in Adolescent Subjects with Plaque Psoriasis SKIN The Journal of Cutaneous Medicine, 3 2